Hester Biosciences reported Q1 standalone revenue up 14% to 72.66 Cr, with PAT up 88% to 14.71 Cr, driven by strong poultry segment growth.

Consolidated revenue declined 8% to 77.24 Cr.

Consolidated PAT surged 459% to 96.73 Cr, boosted by an exceptional 85.35 Cr gain from a Gates Foundation loan amendment in Africa.